| Document |
Document Title |
|
WO/2003/005956A2 |
The present invention concerns the generation of hydroxamic acid thrombospondin-peptide analogs that inhibit aggrecanase activity. These analogs are useful in the treatment of diseases characterized by cartilage degradation, such as oste...
|
|
WO2003002522A1 |
PDF inhibitors and novel methods for their use are provided.
|
|
WO/2003/002522A2 |
PDF inhibitors and novel methods for their use are provided.
|
|
WO/2002/100812A1 |
A medicine containing as the active ingredient a novel carboxylic acid derivative useful as an insulin resistance ameliorant. The carboxylic acid derivative is represented by the following general formula (I). Also provided are a salt or...
|
|
WO/2002/100341A2 |
Compounds useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis, are disclosed.
|
|
WO/2002/098901A2 |
Novel PDF inhibitors and novel methods for their use are provided.
|
|
WO/2002/092553A1 |
This invention relates to new compounds, pharmaceutical compositions and diagnostic kits comprising such compounds, and methods of using such compounds for inhibiting NAALADase enzyme activity, detecting diseases where NAALADase levels a...
|
|
WO/2002/088071A1 |
Hydroxyformamidine compounds represented by the following general formula or pharmaceutically acceptable salts thereof: wherein R1 represents substituted morpholino, substituted piperidino, piperazin−1−yl, substituted piperazin−1âˆ...
|
|
WO/2002/085883A1 |
Compounds of formula (I), wherein R¿1?, R¿2?, A, X, Y and Z have the meanings defined in the specification, process of manufacturing these compounds and pharmaceuticals with HDAC inhibitor activity containing such a compound.
|
|
WO/2002/081426A1 |
PDF inhibitors and novel methods for their use are provided.
|
|
WO/2002/079144A1 |
The invention relates to the (p-amino-hydroxyphenyl)-acrylamide derivatives of general formula (I), or the physiologically acceptable, water-soluble salts thereof, and to oxidative dyes for keratin fibers containing said compounds.
|
|
WO/2002/079136A1 |
A method of forming a cyclopropane having enhanced chirality said method comprising reacting together (1), a symmetrical 1,2-dioxine of the formula (1), wherein X and Y are the same and are groups in which a carbon atom is bonded to the ...
|
|
WO/2002/076941A2 |
Histone deacetylase is a metallo-enzyme with zinc at the active site. Compounds having a zinc-binding moiety, such as, for example, a hydroxamic acid group or a carboxylic acid group, can inhibit histone deacetylase. Histone deacetylase ...
|
|
WO/2002/076395A2 |
Agents and methods for chemoprevention and treatment of neoplasia are described, the agents including a selective inhibitor of inducible nitric oxide synthase and a combination of a selective inhibitor of inducible nitric oxide synthase ...
|
|
WO/2002/074731A1 |
The invention relates to 3-(2,5-diaminophenyl)-acrylamide derivatives of general formula (I) or the physiologically acceptable, water-soluble salts thereof, in addition to agents containing said compounds for colouring fibres in an oxida...
|
|
WO/2002/074298A1 |
IL-6 production inhibitors containing as the active ingredient hydroxamic acid derivatives represented by the following general formula (I) or equivalents thereto, non-toxic salts thereof or prodrugs of the same, (I) wherein each symbol ...
|
|
WO/2002/074296A1 |
Preventives and/or remedies for solid cancer which contain as the active ingredient hydroxamic acid derivatives represented by the following general formula (I): wherein each symbol is as defined in the description; non-toxic salts there...
|
|
WO/2002/070541A2 |
Nobel PDF inhibitors and novel methods for their use are provided.
|
|
WO/2002/068379A2 |
New types of hydroxamic acid-based bifunctional chelators are provided. These chelators are designed to chelate metal ions that can be detected either by their paramagnetic or radioactive properties. Conjugation with peptides or protein ...
|
|
WO2002042250B1 |
The invention concerns the field of synthesis organic chemistry applied to the pharmaceutical field and concerns novel derivatives of 4-hydrxoybutanoic acid and of its higher homologue, 5-hydroxypentanoic acid, their crotonic homologues,...
|
|
WO/2002/053146A2 |
The present invention provides compounds that are effective in treating disorders caused by the enzymatic activity of matrix metalloproteinases. These disorders include, but are not limited to, rheumatoid arthritis, osteoarthritis, perio...
|
|
WO/2002/050019A2 |
The present application describes modulators of MCP-1 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma, multiple sclerosis, atherosclerosis, and rheumatoid arthritis.
|
|
WO/2002/050081A2 |
Compounds of formula (I) and (IA) have antibacterial or antiprotozoal activity: formula (1) formula (2) wherein: Z represents a radical of formula N(OH)CH(=O) or of formula C(=O)NH(OH); R¿1? represents hydrogen, methyl or trifluoromethy...
|
|
WO/2002/050046A1 |
Compound of formula (I), wherein X is C¿1-6? alkylene or C¿2-6? alkenylene, each of which is optionally substituted by one or more flluorine atoms; R is aryl or C¿3-8? cycloalkyl optionally substituted by one or more fluorine atoms; W...
|
|
WO/2002/046144A1 |
Compounds of formula (I) wherein R1, R2, R3, R4, R5, X and Y have the meanings defined below, process of manufacturing these compounds and pharmaceuticals containing such a compound have HDAC inhibitor activity. R1 is selected from hydro...
|
|
WO/2002/044131A1 |
Novel substituted carboxylic acid derivatives which bind to human peroxisome proliferator-activated receptor $g(a) (PPAR$g(a)) as a ligand thereof and activate the same to thereby exert a lipid-lowering effect, an arteriosclerosis-preven...
|
|
WO/2002/042248A2 |
The present invention relates to naphthalene derivatives of formula (I), wherein X is S, S(O), S(O)¿2?, S(O)¿2?NH, P(O)OCH¿3?, P(O)OH, NH, N(CH¿3?), NHC(O)NH, C(O), C(O)O, NHC(O), CH(OH), CH=N, CH=CH, CH¿2?NH, C(=NH); R?1¿ is aryl ...
|
|
WO/2002/038596A1 |
The present invention relates to peptides having eubacterial b protein-binding properties and the surface of b protein with which said peptides and other proteins interact. The invention provides in vitro and in vivo assays for identifyi...
|
|
WO/2002/034260A1 |
The present invention provides compositions useful for the treatment of inflammation in humans, and related methods of treatment for the same. In one embodiment the composition is In another embodiment, the composition is In yet another ...
|
|
WO/2002/034711A1 |
Compounds of formula (I) are useful as inhibitors of trypsin like serine protease enzymes such as thrombin, factor VIIa, factor Xa, TF/FVIIa, and trypsin. These compounds could be useful to treat and/or prevent clotting disorders, and as...
|
|
WO/2002/030873A1 |
A novel MMP inhibitor. It is a compound represented by the formula (I) or a salt thereof: (I) wherein R?1¿ and R?2¿ each means optionally substituted aryl, optionally substituted lower arylalkyl, lower arylalkenyl, lower aryloxyalkyl, ...
|
|
WO2002012210A9 |
The invention concerns compounds of formula (I) wherein: R1 represents a radical of formula (a) or (b); Y represents a CH2 radical or a sulphur atom; R5 represents a hydroxy radical, an alkoxy radical, a NH-OH radical, or a N(R8)(R9) rad...
|
|
WO/2002/028829A2 |
The invention is directed to a novel class of compounds, which inhibits peptide deformylase, pharmaceutical compositions containing compounds that inhibit peptide deformylase, and method of treating various infections.
|
|
WO/2002/026696A1 |
This invention pertains to certain active carbamic acid compounds which inhibit HDAC activity and which have the formula (1) wherein: A is an aryl group; Q?1¿ is an aryl leader group having a backbone of at least 2 carbon atoms; J is an...
|
|
WO/2002/026703A1 |
This invention pertains to certain active carbamic acid compounds which inhibit HDAC activity and which have the following formula(I) wherein: A is an aryl group; Q?1¿ is a covalent bond or an aryl leader group; J is an amide linkage se...
|
|
WO/2002/024613A2 |
The present invention relates to certain resorcinol derivatives and their use as skin lightening agents.
|
|
WO/2002/022562A1 |
The present invention relates to 2-amino-2-alkyl-5 heptenoic and heptynoic acid derivatives and their use in therapy, in particular their use as nitric oxide synthase inhibitors.
|
|
WO/2002/022559A2 |
The present invention relates to 2-amino-2-alkyl-4 hexenoic and hexynoic acid derivatives and their use in therapy, in particular their use as nitric oxide synthase inhibitors.
|
|
WO/2002/022577A2 |
The present invention provides hydroxamate compounds of formula (I) which are deacetylase inhibitors. The compounds are suitable for pharmaceutical compositions having anti-proliferative properties.
|
|
WO/2002/020467A1 |
Novel crystals of compound (I): (I) According to this invention, the compound (I) useful as a drug (matrix metalloproteinase inhibitor) can be provided as stable crystals capable of keeping constant quality.
|
|
WO/2002/019967A2 |
A method for the inhibition of high affinity glycine transporters, compounds that inhibit these transporters; pharmaceutically active compositions comprising such compounds; and the use of such compounds either as above, or in formulatio...
|
|
WO/2002/018326A1 |
Propenohydroxamic acid derivatives represented by the following general formula (1) or salts thereof and drugs containing the same: (1) wherein R?1¿ represents hydrogen, alkyl or halogeno; R?2 ¿represents cycloalkyl, aryl, heteroaryl, ...
|
|
WO/2002/018321A2 |
Compound of formula (I) or therapeutically acceptable salts thereof, are protein tyrosine kinase PTP1B inhibitors. Preparation of the compounds, compositions containing the compounds, and treatment of diseases using the compounds are dis...
|
|
WO/2002/018319A1 |
The present invention relates to a process for the preparation of N-arylanthranilic acids, and a process for the preparation of N-aryl anthranilic esters, amides, and hydroxamic esters.
|
|
WO/2002/012220A2 |
A more practical synthesis for preparing discodermolide and structurally related analogues, novel compounds useful in the process and novel compounds prepared by the process.
|
|
WO/2002/010122A1 |
A method for preparing fatty hydroxamic acids and salts thereof comprising reacting a fatty acid derivative with an aqueous solution of a hydroxylamine.
|
|
WO/2002/006213A2 |
The present invention relates to oxygenated esters of 4-iodophenylamino benzhydroxamic acid derivatives, pharmaceutical compositions and methods of use thereof. The present invention also relates to crystaline forms of oxygenated esters ...
|
|
WO/2002/000593A2 |
Formula (I) compounds are described, where R¿1? and R¿2?, which may be the same or different, are halogen, hydroxy, alkoxy, cycloalkoxy; X is (CH¿2?)¿n?-, -CO-(CH¿2?)¿n?-, where n is 1 or 2, or X is -CH=; R¿3? is -OH, -NHOH, alkox...
|
|
WO/2002/000590A1 |
The invention is directed to the cross-metathesis and ring-closing metathesis reactions between geminal disubstituted olefins and terminal olefins, wherein the reaction employs a Ruthenium or Osmium metal carbene complex. Specifically, t...
|
|
WO/2002/000609A2 |
Formula (I) compounds are described where the groups are as defined in the description, as well as processes for their preparation and their use as medicaments, particularly for the preparation of medicaments with phosphodiesterase IV in...
|
